Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2020

View Archived Issues

Faulty exon splicing is cause of rare subtype of Parkinson's disease, pointing to new drug targets

Positive preclinical data for novel COVID-19 vaccine, ACvac1

Key initial results reported from phase I study of CPI-006 for patients with COVID-19

FDA clears IND for phase I study of APR-003

Room for improvement in T-cell repertoire profiling

Results from phase II CENTAUR study of sodium phenylbutyrate/taurursodiol in ALS

Voronoi patents new RET inhibitors

Galapagos discloses PASK inhibitors

Aerie Pharmaceuticals presents new Rho and JAK inhibitors

Discovery of novel orally active and selective PI3Kalpha inhibitor

Constellation Pharmaceuticals discovers new CBP and KAT3B inhibitors

New phase II trial examines suprachoroidal administration of AU-011 in primary choroidal melanoma

Proof-of-concept study of ziritaxestat in diffuse cutaneous systemic sclerosis meets endpoint

New antibacterials presented by Viridias

Topadur begins phase I study of TOP-N53 for wound healing

QBW-251: a CFTR potentiator in phase II for the treatment of COPD

Phase III trial of Fasenra in nasal polyposis meets coprimary endpoints

Bicycle opens phase I/II study of BT-8009 in advanced solid tumors

FCN-437c enters phase II trial in China for advanced breast cancer

Pentamidine targets S100B to improve experimental multiple sclerosis

SanBio reports new phase IIb analyses for SB-623 in chronic motor deficit from ischemic stroke

Gemini begins phase IIa study of GEM-103 for dry AMD

Novartis describes discovery and clinical results with ERK1/2 inhibitor LTT-462

Sutro reports updated phase I data on STRO-002 in advanced ovarian cancer

KITE study of Beovu in DME meets primary and key secondary endpoints

Dimerix reports phase II data on DMX-200 in diabetic kidney disease

Enanta begins phase I study of EDP-297 for NASH

FDA approves Trelegy Ellipta for asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...